Last reviewed · How we verify

NCT03534024

The Effects of Nanomicelles Curcumin on Glycemic Control, Serum Lipid Profile ,Blood Pressure and Anthropometric Measurements in Patients With Metabolic Syndrome

Status unknown NA Last updated 31 July 2018
What this trial tests

NA trial testing nanomicielle curcumin in Metabolic Syndrome in 50 participants. Status unknown.

Timeline
30 August 2018
Primary endpoint
30 August 2019
30 January 2020

Quick facts

Lead sponsorNational Nutrition and Food Technology Institute
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposesupportive care
Enrollment50
Start date30 August 2018
Primary completion30 August 2019
Estimated completion30 January 2020
Sites1 location across Iran

Drugs / interventions tested

Conditions studied

Sponsor

National Nutrition and Food Technology Institute

Who can join

Adults 18 to 70, any sex, with Metabolic Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Metabolic syndrome is a condition which is recognized by abdominal obesity, dyslipidemia, hyperglycemia, and hypertension. Curcumin has beneficial effects such as antioxidant and anti-inflammatory effects. nanomcielle curcumin will be used in this study because of the low bioavailability , fast metabolism and low absorption of curcumin powder. Therefore, this study is planned to determine the effects of supplementation of nanomicelle curcumin on glycemic control, serum lipid profile ,blood pressure and anthropometric measurements in patients with metabolic syndrome.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Nanocurcumin: A Promising Candidate for Therapeutic Applications.
    Karthikeyan A, Senthil N, Min T. · · 2020 · cited 200× · PMID 32425772 · DOI 10.3389/fphar.2020.00487
  2. Nanocarriers for the Delivery of Medical, Veterinary, and Agricultural Active Ingredients.
    Chariou PL, Ortega-Rivera OA, Steinmetz NF. · · 2020 · cited 101× · PMID 32125825 · DOI 10.1021/acsnano.0c00173
  3. A Comprehensive Review on the Benefits and Problems of Curcumin with Respect to Human Health.
    Liu S, Liu J, He L, Liu L, et al · · 2022 · cited 77× · PMID 35889273 · DOI 10.3390/molecules27144400
  4. Curcuma Longa (turmeric): from traditional applications to modern plant medicine research hotspots.
    Tian WW, Liu L, Chen P, Yu DM, et al · · 2025 · cited 5× · PMID 40437595 · DOI 10.1186/s13020-025-01115-z
  5. Transcriptional and epigenetic regulation of autophagy: mechanisms, disease relevance and therapeutic opportunities.
    Seo J, Park SY, Lee DC, Yoo W, et al · · 2026 · PMID 42236674 · DOI 10.1038/s41392-026-02688-3

Verify or expand the search:

Other trials of nanomicielle curcumin

Trials testing the same drug.

Other recruiting trials for Metabolic Syndrome

Currently open trials in the same condition.

Other National Nutrition and Food Technology Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03534024.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing